As­pen looks to re­bound in pro­duc­tion and rev­enue af­ter Covid-19

Last year, South African-based vac­cine man­u­fac­tur­er As­pen Phar­ma­care was fac­ing re­ports that it had not re­ceived a sin­gle or­der for its man­u­fac­tured Covid-19 shots and that man­u­fac­tur­ing lines were sit­ting idle. But now the vac­cine pro­duc­er is look­ing to turn things around.

As­pen’s dis­clo­sure of its fi­nan­cial re­sults in March un­veiled that man­u­fac­tur­ing rev­enue had de­creased by 12% to R 603 mil­lion ($33.8 mil­lion), which Lor­raine Hill, As­pen Group’s COO, said is at­trib­ut­able to low­er Covid vac­cine sales.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN